Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

643 trials with published results (12%)

Research Maturity

2890 completed trials (55% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.8%

415 terminated out of 5291 trials

Success Rate

87.4%

+0.9% vs benchmark

Late-Stage Pipeline

13%

669 trials in Phase 3/4

Results Transparency

22%

643 of 2890 completed with results

Key Signals

643 with results87% success415 terminated

Data Visualizations

Phase Distribution

3,135Total
Not Applicable (1131)
Early P 1 (30)
P 1 (449)
P 2 (856)
P 3 (485)
P 4 (184)

Trial Status

Completed2,890
Unknown1,377
Terminated415
Withdrawn281
Recruiting135
Active Not Recruiting129

Trial Success Rate

87.4%

Benchmark: 86.6%

Based on 2890 completed trials

Clinical Trials (5291)

Showing 20 of 20 trials
NCT07536308Phase 1RecruitingPrimary

A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

NCT07856576Not ApplicableCompleted

Effect of a Social-Support-Based Educational Intervention on COVID-19-Related Anxiety and Perceived Social Support in Pregnant Women: A Randomized Pretest-Posttest Controlled Trial

NCT07149428Enrolling By Invitation

Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

NCT04956887Not ApplicableCompletedPrimary

Cognitive Training in Survivors of Covid-19: A Randomized Trial

NCT04401475Phase 2TerminatedPrimary

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19

NCT05699369Not ApplicableCompleted

Interventions to Improve Non-communicable Disease Management During the Pandemic

NCT06076421Not ApplicableCompletedPrimary

Equity Evaluation of Fact Boxes on Informed COVID-19 and Influenza Vaccination Decisions - Study Protocol

NCT05401773CompletedPrimary

α-synuclein Seeding Activity in the Olfactory Mucosa in COVID-19

NCT05369611CompletedPrimary

COVID-19 Experiences in the SELF Cohort

NCT04634799Phase 1TerminatedPrimary

Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

NCT06631287Phase 3Recruiting

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT05605093Phase 3TerminatedPrimary

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

NCT07834073Phase 4CompletedPrimary

Immunogenicity and Safety of a Single Dose of mRNA SARS-CoV-2 Vaccine in Chinese Adults With Hybrid Immunity

NCT04352348Not ApplicableCompletedPrimary

Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being

NCT05886816Phase 2Completed

Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19

NCT04359836Suspended

A Study to Explore the Role of Gut Flora in COVID-19 Infection

NCT06928051Phase 2CompletedPrimary

A Study of S-892216 in Participants With COVID-19

NCT04964115Active Not RecruitingPrimary

Post Acute Sequelae of COVID-19

NCT04393961Not ApplicableWithdrawn

At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study

NCT04411147Active Not RecruitingPrimary

A Longitudinal Study of COVID-19 Sequelae and Immunity

Scroll to load more

Research Network

Activity Timeline